---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-26-030677"
form_type: "8-K"
ticker: "AZTA"
cik: "0000933974"
company_name: "Azenta, Inc."
filed_at: "2026-05-05T23:59:59+00:00"
generated_at: "2026-05-14T23:46:34.475558+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Azenta Q2 revenue $145M, GAAP EPS -$3.41; cuts FY2026 guidance, extends long-range plan to 2029

## Summary
- Organic revenue declined 3% YoY; $149M non-cash goodwill impairment on Multiomics unit.
- FY2026 organic growth guidance cut to -2% to +1% (prev. 3-5%); Adj. EBITDA margin now -125bps to flat.
- Long-range plan extended from 2028 to 2029; B Medical Systems sale delayed due to buyer financing.
- Non-GAAP diluted EPS -$0.04 vs. +$0.01 prior year; cash and securities $565M; no share repurchases yet.

## SEC filing metadata
- accession: 0001628280-26-030677
- form_type: 8-K
- ticker: AZTA
- cik: 0000933974
- company_name: Azenta, Inc.
- filed_at: 2026-05-05T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/933974/000162828026030677/0001628280-26-030677-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/933974/000162828026030677/azta-20260505.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-26-030677
- JSON: https://secwatch.observer/filing/0001628280-26-030677.json
- Plain text: https://secwatch.observer/filing/0001628280-26-030677.txt

## Key facts
- Earnings Releases
  Azenta, Inc. reported the fiscal quarter ended March 31, 2026 results: revenue $145 million, EPS ($3.41). Guidance lowered.
  - Period: the fiscal quarter ended March 31, 2026
  - Revenue: $145 million
  - EPS: ($3.41)
  - Guidance: lowered
  - Result: reported results
  source text: position Azenta for improved execution, greater consistency, and profitable long‐term value creation.” Second Quarter Fiscal 2026 Results - Continuing Operations • Revenue was $145 million, up 1% year over year. Organic revenue, which excludes a 3-percentage point impact from foreign exchange and a 1-percentage point from the acquisition of UK Biocentre Limited,
  evidence_url: https://www.sec.gov/Archives/edgar/data/933974/000162828026030677/0001628280-26-030677-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.